DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Baselga J, Bradbury I, Eidtmann H. et al. NeoALTTO Study Team.
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
Lancet 2012;
379 (9816) 633-640
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.